Ondine Announces Ventilator Associated Pneumonia (VAP) Photodisinfection Clinical Study in the US

 
TIDMOBP 
 
Ondine Announces Ventilator Associated Pneumonia (VAP) Photodisinfection Clinical Study in the US 
FOR:  ONDINE BIOMEDICAL INC. 
 
TSX, AIM SYMBOL:  OBP 
 
May 10, 2011 
 
Ondine Announces Ventilator Associated Pneumonia (VAP) Photodisinfection Clinical Study in the US 
 
VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 10, 2011) - Ondine Biomedical Inc. (the "Company" or "Ondine") 
(TSX:OBP)(AIM:OBP), a medical technology company developing photodisinfection based products, today announced 
that the United States Food and Drug Administration (FDA) has approved a human clinical study (the "Study") to 
investigate the use of photodisinfection for the in situ microbial disinfection of endotracheal tubes as a 
means to prevent ventilator associated pneumonia (VAP). VAP is the number one cause of healthcare-associated 
infections in intensive care unit patients. 
 
The photodisinfection treatment system to be used in the study was developed by Ondine's wholly owned 
subsidiary, Advanced Photodynamic Technologies, Inc. (APT). Funding of the study site and investigator costs as 
well as all fees incurred to perform all independent clinical study monitoring requirements, data base 
management and statistical analyses is via the direct payment of these costs by a third party under the terms 
of a government grant. APT will be responsible for, among other things, providing at its cost the study 
devices, consisting of the lasers and the photosensitizing agent. The clinical study, which involves one 
clinical site, is expected to commence in the third quarter of 2011 and to take at least one year to complete. 
 
"A successful VAP study would represent a key step towards the commercialization of this new application of 
photodisinfection which utilizes Ondine's patented technology and products," said Carolyn Cross, Chairman & CEO 
of Ondine. "The leading cause of patient death from healthcare-associated infections is pneumonia. Ventilator 
associated pneumonia is a life threatening infection that occurs in patients who are intubated with an 
endotracheal tube and require mechanical ventilation. In the US, of the 1.3 million patients who require 
mechanical ventilation annually, 10% to 25% will develop VAP with 24% to 50% of these patients consequently 
dying from the infection. The cost of treating VAP in the United States has been estimated to be US$1.2 Billion 
annually and as photodisinfection has been proven to be highly effective at eliminating biofilms in ex vivo 
models, it is therefore ideally suited for the elimination of endotracheal tube biofilms resulting in the 
prevention of VAP." 
 
About Ondine Biomedical Inc. 
 
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and 
viral infections. The Company is focused on developing leading edge products utilizing its patented light- 
activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection 
provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic 
resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development 
laboratory in Bothell, Washington, USA. For additional information, please visit the Company's website at: 
www.ondinebio.com. 
 
Forward-Looking Statements: 
 
Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and 
other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. 
Factors that could cause actual results to differ materially from those projected in the Company's forward- 
looking statements include the following: market acceptance of our technologies and products; our ability to 
obtain financing; our financial and technical resources relative to those of our competitors; our ability to 
keep up with rapid technological change; government regulation of our technologies; our ability to enforce our 
intellectual property rights and protect our proprietary technologies; the ability to obtain and develop 
partnership opportunities; the timing of commercial product launches; the ability to achieve key technical 
milestones in key products and other risk factors identified from time to time in the Company's public filings. 
 
 
-30- 
 
FOR FURTHER INFORMATION PLEASE CONTACT: 
 
Ondine Biomedical Inc. 
Carolyn Cross 
Chairman and CEO 
[e-mail] 
www.ondinebio.com 
 
OR 
 
Canaccord Genuity Limited 
Mark Williams/Bhavesh Patel 
Nominated Adviser 
[phone] 
 
The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this 
release. 
 
 
 
 
Ondine Biomedical Inc.